MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
DENTSPLY SIRONA Income Statement 2011-2026 | XRAY
Annual Income Statement DENTSPLY SIRONA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.52 B | 3.5 B | 6.88 B | 7.99 B | 11.6 B | 11.6 B | 12.3 B | 9.32 B | 14.1 B | 12.3 B | 8.24 B | 7.09 B | 6.65 B | 5.95 B | 5.35 B |
Shares |
199 M | 203 M | 212 M | 215 M | 217 M | 219 M | 223 M | 224 M | 229 M | 218 M | 140 M | 142 M | 143 M | 142 M | 141 M |
Historical Prices |
12.7 | 17.2 | 32.5 | 37.1 | 53.4 | 53.2 | 55.2 | 41 | 59 | 54.7 | 56.5 | 47.7 | 43.8 | 39.4 | 35.4 |
Net Income |
-598 M | -910 M | -132 M | -950 M | 411 M | -73 M | 256 M | -1.01 B | -1.55 B | 430 M | 251 M | 323 M | 313 M | 314 M | 245 M |
Revenue |
3.68 B | 3.79 B | 3.96 B | 3.92 B | 4.23 B | 3.34 B | 4.02 B | 3.99 B | 3.99 B | 3.75 B | 2.67 B | 2.92 B | 2.95 B | 2.93 B | 2.54 B |
Cost of Revenue |
1.84 B | 1.84 B | 1.88 B | 1.8 B | 1.88 B | 1.68 B | 1.86 B | 1.92 B | 1.8 B | 1.74 B | - | - | - | - | - |
Gross Profit |
1.84 B | 1.96 B | 2.09 B | 2.13 B | 2.35 B | 1.66 B | 2.16 B | 2.07 B | 2.19 B | 2 B | 1.52 B | 1.6 B | 1.58 B | 1.56 B | 1.27 B |
Operating Income |
-422 M | -879 M | -85 M | -937 M | 608 M | -3 M | 353 M | -958 M | -1.56 B | 455 M | 375 M | 446 M | 419 M | 382 M | 301 M |
Interest Expense |
24 M | 12 M | -9 M | -53 M | 61 M | -1 M | 12 M | 37.3 M | 38.3 M | 35.9 M | 55.9 M | 46.9 M | 49.6 M | 56.9 M | 43.8 M |
EBITDA |
-70 M | -530 M | 258 M | -609 M | 955 M | 331 M | 676 M | 680 M | 830 M | 750 M | 563 M | 586 M | 560 M | 537 M | 422 M |
Operating Expenses |
- | - | - | - | - | - | - | 1.72 B | 1.67 B | 1.52 B | 1.08 B | 1.14 B | 1.14 B | 1.15 B | 937 M |
General and Administrative Expenses |
1.44 B | 1.6 B | 1.61 B | 1.59 B | 1.55 B | 1.3 B | 1.59 B | 1.72 B | 1.67 B | 1.52 B | 1.08 B | 1.14 B | 1.14 B | 1.15 B | 937 M |
All numbers in USD currency
Quarterly Income Statement DENTSPLY SIRONA
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
200 M | 199 M | 199 M | 199 M | 201 M | 206 M | 207 M | 207 M | 212 M | 212 M | 214 M | 215 M | 215 M | 215 M | 217 M | 217 M | 219 M | 218 M | 219 M | 219 M | 218 M | 219 M | 221 M | 221 M | 223 M | 224 M | 223 M | 223 M | 222 M | 225 M | 227 M | 227 M | 230 M | 229 M | 230 M | 230 M | 233 M | 234 M | 175 M | 140 M | 140 M | 140 M | 140 M | 141 M | 142 M | 142 M | 142 M | 142 M | 142 M | 143 M | 143 M | 142 M | 142 M | 143 M | 142 M | 142 M | 141 M | 141 M | 142 M |
Net Income |
-427 M | -45 M | 20 M | - | -494 M | -4 M | 18 M | - | -266 M | 86 M | -19 M | - | -1.08 B | 73 M | 69 M | - | 84 M | 96 M | 112 M | - | 53 M | -95 M | -140 M | 102 M | 85 M | 36.4 M | 39.2 M | 1.8 M | 28 M | -1.12 B | 81.2 M | -650 M | 90.6 M | -1.05 B | 59.7 M | 107 M | 92.5 M | 105 M | 125 M | 58.6 M | 84.5 M | 44.1 M | 64 M | 84.7 M | 75.3 M | 90 M | 72.9 M | 74.4 M | 79.9 M | 87.2 M | 71.7 M | - | 53.4 M | 80.8 M | 53.3 M | - | 60.6 M | 74.2 M | 69.1 M |
Revenue |
904 M | 936 M | 879 M | - | 951 M | 984 M | 953 M | - | 947 M | 1.03 B | 978 M | - | 947 M | 1.02 B | 969 M | - | 1.04 B | 1.06 B | 1.03 B | - | 895 M | 491 M | 874 M | 1.11 B | 962 M | 1.01 B | 946 M | 1.06 B | 928 M | 1.04 B | 956 M | 1.09 B | 1.01 B | 993 M | 900 M | 996 M | 954 M | 1.02 B | 773 M | 671 M | 649 M | 698 M | 656 M | 719 M | 708 M | 765 M | 730 M | 754 M | 704 M | 761 M | 732 M | - | 696 M | 763 M | 716 M | - | 620 M | 609 M | 571 M |
Cost of Revenue |
463 M | 446 M | 413 M | - | 456 M | 473 M | 447 M | - | 452 M | 478 M | 459 M | - | 439 M | 442 M | 448 M | - | 471 M | 467 M | 447 M | - | 453 M | 315 M | 406 M | - | 448 M | 469 M | 446 M | - | 452 M | 489 M | 442 M | - | 450 M | 448 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
441 M | 490 M | 466 M | - | 495 M | 511 M | 506 M | - | 495 M | 550 M | 519 M | - | 508 M | 581 M | 521 M | - | 569 M | 595 M | 579 M | - | 442 M | 176 M | 468 M | 611 M | 514 M | 541 M | 500 M | 525 M | 476 M | 553 M | 514 M | 593 M | 559 M | 544 M | 492 M | 542 M | 514 M | 527 M | 419 M | 375 M | 369 M | 400 M | 373 M | 393 M | 388 M | 424 M | 394 M | 398 M | 376 M | 415 M | 388 M | - | 364 M | 407 M | 393 M | - | 298 M | 315 M | 300 M |
Operating Income |
-218 M | -128 M | 63 M | - | -462 M | 50 M | 42 M | - | -236 M | 80 M | -2 M | - | -1.22 B | 119 M | 97 M | - | 132 M | 154 M | 150 M | - | 82 M | -104 M | -125 M | 137 M | 110 M | 67.5 M | 47.3 M | 81.8 M | 45.5 M | -1.15 B | 68.7 M | -706 M | 108 M | -1.05 B | 84.2 M | 134 M | 127 M | 121 M | 72.7 M | 93.1 M | 98.6 M | 85.8 M | 97.7 M | 103 M | 110 M | 127 M | 106 M | 97.4 M | 105 M | 123 M | 93.9 M | - | 88.7 M | 109 M | 87.2 M | - | 39.8 M | 97 M | 98.6 M |
Interest Expense |
11 M | -1 M | - | - | 2 M | 1 M | 7 M | - | 5 M | -12 M | 20 M | - | 14 M | 15 M | 12 M | - | 14 M | 15 M | 14 M | - | 14 M | 11 M | 7 M | - | 6.6 M | 8 M | 8.4 M | - | 9.7 M | 9.6 M | 8.6 M | - | 9.8 M | 9.6 M | 9.3 M | - | 8.4 M | 9.3 M | 9.2 M | - | 9.6 M | 9.8 M | 10.7 M | - | 12.7 M | 11.8 M | 11 M | - | 11.4 M | 11.5 M | 15.2 M | - | 13.9 M | 14.3 M | 15.8 M | - | 16.1 M | 5.57 M | 6.34 M |
EBITDA |
-126 M | -40 M | 142 M | - | -373 M | 136 M | 128 M | - | - | - | 29 M | - | -1.13 B | 178 M | 126 M | - | 226 M | 218 M | 182 M | - | 186 M | -39 M | -93 M | 137 M | 211 M | 138 M | 82.2 M | 81.8 M | 149 M | -1.09 B | 102 M | -706 M | 202 M | -986 M | 115 M | 134 M | 214 M | 176 M | 96.2 M | 93.1 M | 160 M | 125 M | 117 M | 103 M | 173 M | 169 M | 127 M | 97.4 M | 167 M | 165 M | 114 M | - | 148 M | 149 M | 107 M | - | 86.9 M | 129 M | 114 M |
General and Administrative Expenses |
355 M | 342 M | 358 M | - | 390 M | 399 M | 415 M | - | 372 M | 416 M | 416 M | - | 401 M | 410 M | 376 M | - | 395 M | 393 M | 386 M | - | 315 M | 261 M | 359 M | - | 399 M | 431 M | 432 M | - | 418 M | 432 M | 435 M | - | 430 M | 418 M | 405 M | - | 379 M | 402 M | 342 M | - | 264 M | 275 M | 270 M | - | 276 M | 296 M | 288 M | - | 269 M | 290 M | 294 M | - | 260 M | 296 M | 304 M | - | 231 M | 211 M | 201 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company DENTSPLY SIRONA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 75.8 | -0.08 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
$ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.96 | -0.75 % | $ 183 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
$ 6.18 | -0.08 % | $ 52.4 K | USA |
 |
ICU Medical
ICUI
|
$ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.8 | -0.89 % | $ 4.5 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 482.22 | 0.71 % | $ 172 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 10.34 | 0.68 % | $ 214 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
$ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
$ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
BioLife Solutions
BLFS
|
$ 21.38 | -1.57 % | $ 985 M | USA |
 |
Stereotaxis
STXS
|
$ 1.93 | -1.53 % | $ 176 M | USA |
 |
Baxter International
BAX
|
$ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
$ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
AtriCure
ATRC
|
$ 29.28 | 3.79 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.86 | 1.18 % | $ 305 M | USA |
 |
Utah Medical Products
UTMD
|
$ 67.17 | -1.03 % | $ 218 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.1 | -0.89 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
$ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.0 | -1.64 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
$ 117.6 | 3.1 % | $ 6.55 M | USA |